Daraxonrasib: A Potential Game-Changer For Pancreatic Cancer
- A targeted therapy currently under investigation could be one of the biggest advances in pancreatic cancer treatment in years.
- In a phase 3 clinical trial, daraxonrasib improved overall survival to 13.2 months, nearly double the 6.7 months seen with conventional chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
- Daraxonrasib targets mutations in RAS proteins, which are incredibly common in pancreatic cancer tumors. It is taken in pill form, unlike standard intravenous chemotherapy regimens.
- “The news from [drugmaker] Revolution Medicines that their RAS inhibitor, called daraxonrasib, approximately doubles overall survival in patients with previously treated, metastatic pancreatic cancer is huge,” Dr. Anna Berkenblit, Chief Scientific and Medical Officer at Pancreatic Cancer Action Network (PanCAN), tells SurvivorNet. “This is a truly remarkable result.”
- The initial patient population for daraxonrasib, if approved, would be those with previously treated metastatic PDAC, where the unmet need is highest.
In a phase 3 clinical trial, daraxonrasib, which targets mutations in RAS proteins, showed marked improvement in survival compared to conventional chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Read MoreExpert Resources for Pancreatic Cancer Patients
- Immunotherapy Offers New Hope for Fighting Pancreatic Cancer
- New Drug Approved for Advanced Pancreatic Cancer Could Reduce Risk of Disease Progression by 47%
- New Drug to Keep Some Pancreatic Cancers from Worsening Takes a Giant Step Forward
- Pancreatic Cancer Rates are Rising In Women Aged 15 to 34, According to New Research; How To Recognize Symptoms
Who Can Benefit From Daraxonrasib?
The patients included in the phase 3 study had metastatic PDAC that was refractory (non-responsive) to prior treatment, but Dr. Berkenblit predicts that the drug may have uses in earlier stage disease as well.
“If the FDA approves the drug after reviewing the efficacy and safety data, the initial population would be patients with previously treated metastatic pancreatic cancer. That’s just the beginning,” Dr. Berkenblit explains.
Initially, patients would need to meet certain requirements to get daraxonrasib, including:
- Measurable metastatic disease
- An acceptable performance status allowing them to conduct most daily activities
- Well-functioning organs
In the trial, daraxonrasib was compared to the standard chemotherapy.
A Shift In Strategy
If the drug is approved based on trial data, it will indicate a potential shift in the treatment strategy for pancreatic cancer.
Since daraxonrasib is taken in pill form, the experience of taking this medicine is much different from that of intravenous chemotherapy treatments. However, patients will still need close supervision and management of side effects. These are reportedly mild with skin rash, mouth sores, diarrhea, vomiting, nausea, and fatigue being the most common.
Additionally, new cancer drugs are often tested first in advanced or refractory disease, where the unmet need is highest and signals of activity can be detected faster. If the benefits appear real and the safety profile is manageable, the same agent is tested in early-stage settings.
“We anticipate the drug will move up into earlier lines of therapy and not just daraxonrasib, but RAS inhibitors in general,” Dr. Berkenbilt notes.
“If it works this well in patients with previously treated metastatic disease, we’re really excited about the potential of it working even better in frontline or untreated metastatic patients, and maybe even in the adjuvant [after surgery] setting for the small percent of patients who are diagnosed with early-stage, localized disease that can be surgically removed.”
Current Status & Availability
While daraxonrasib has shown impressive results in clinical trials, its widespread accessibility will depend on regulatory approval. As the phase 3 trial in ongoing, it is currently in an “investigational” stage and has not been approved by the U.S. Food and Drug Administration (FDA).
It was granted Breakthrough Therapy Designation by the FDA for the treatment of patients with previously treated, metastatic PDAC with G12 mutations.
Revolution Medicines has said it plans to submit the results to the FDA and other health authorities and to present the data at the 2026 ASCO Annual Meeting, which will kick off on May 29, 2026.
Questions To Ask Your Doctor
- Does my tumor have a RAS mutation?
- Should I consider enrolling in the clinical trial?
- How does this new therapy differ from standard chemotherapy?
- How do the side effects v. potential benefits compare to the standard?
Learn more about SurvivorNet's rigorous medical review process.
